---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-075244"
form_type: "8-K"
ticker: "QNRX"
cik: "0001671502"
company_name: "Quoin Pharmaceuticals, Ltd."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:45:36.685794+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Quoin Pharma Q2 net loss $3.7M; QRX003 advances with FDA/EMA designations

## Summary
- Net loss Q2 2025 $3.7M vs $2.0M YoY; cash $7.8M supports operations into Q1 2026.
- Positive 6-month pediatric Netherton data: skin improvement, reduced itch, no adverse events.
- FDA cleared second pivotal study (CL-QRX003-002); NDA filing targeted later 2026.
- EMA granted Orphan Drug Designation; FDA granted Rare Pediatric Disease Designation for QRX003.
- Positive 12-week Peeling Skin Syndrome data: improved disease severity and quality of life.

## SEC filing metadata
- accession: 0001104659-25-075244
- form_type: 8-K
- ticker: QNRX
- cik: 0001671502
- company_name: Quoin Pharmaceuticals, Ltd.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671502/000110465925075244/0001104659-25-075244-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671502/000110465925075244/tm2522891d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-075244
- JSON: https://secwatch.observer/filing/0001104659-25-075244.json
- Plain text: https://secwatch.observer/filing/0001104659-25-075244.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.